Capnia, Essentialis merge to create rare disease therapeutics company

Monday, January 2, 2017

Capnia and privately held Essentialis have announced their entry into a definitive merger agreement to create a rare disease therapeutics company. The combined company will be well-positioned to advance diazoxide choline controlled release tablet (DCCR), a once-daily oral tablet for the treatment of patients with Prader-Willi syndrome (PWS). PWS is a rare complex genetic neurobehavioral/metabolic disease. The clinical features of the disease include hyperphagia (unrelenting hunger), as well as metabolic, endocrine, cognitive and behavioral complications resulting in significant morbidity and premature death.

[Read More]

Essentialis names Berg CEO

Wednesday, December 7, 2011

Essentialis has promoted Aaron D. Berg from president and chief commercial officer to chief executive officer. Berg joined Essentialis in 2010 bringing business development and product commercialization experience to the company. He was also appointed to the Essentialis board of directors.

[Read More]